Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Net Margin (2020 - 2025)

Barinthus Biotherapeutics' Net Margin history spans 6 years, with the latest figure at 2112600.0% for Q2 2025.

  • For Q2 2025, Net Margin changed N/A year-over-year to 2112600.0%; the TTM value through Dec 2025 reached 20964.67%, down 2055594.0%, while the annual FY2024 figure was 408.73%, 874925.0% up from the prior year.
  • Net Margin reached 2112600.0% in Q2 2025 per BRNS's latest filing, down from 6220.89% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 1671800.0% in Q4 2021 to a low of 2112600.0% in Q2 2025.
  • Average Net Margin over 5 years is 41501.71%, with a median of 3893.8% recorded in 2023.
  • Peak YoY movement for Net Margin: skyrocketed 167526441bps in 2021, then crashed -167212775bps in 2022.
  • A 5-year view of Net Margin shows it stood at 1671800.0% in 2021, then plummeted by -100bps to 327.75% in 2022, then plummeted by -2076bps to 7132.93% in 2023, then soared by 99bps to 54.31% in 2024, then crashed by -3890109bps to 2112600.0% in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Net Margin are 2112600.0% (Q2 2025), 6220.89% (Q1 2025), and 54.31% (Q3 2024).